SignatureFD’s Zevra Therapeutics ZVRA Stock Holding History

SignatureFD’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-299	Closed	-$2.24K	–	3449
2025 Q1	$2.24K	Buy	299 +118	+65%	+$938	﹤0.01%	2847
2024 Q4	$1.51K	Hold	181	–	–	﹤0.01%	2948
2024 Q3	$1.26K	Buy	+181	New	+$1.23K	﹤0.01%	2953
2021 Q2	–	Sell	-200	Closed	-$2K	–	3084
2021 Q1	$2K	Buy	+200	New	+$1.75K	﹤0.01%	2547

Other funds holding ZVRA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

SignatureFD's ZVRA Position: Q2 2025 in Review

SignatureFD sold out of Zevra Therapeutics (ZVRA) in Q2 2025, closing a stake of 299 shares — an estimated $2.24K sold.

SignatureFD first reported a position in ZVRA in Q1 2021 and held it in 4 quarters. The position peaked at $2.24K in Q1 2025. 120 funds tracked by Wall St. Rank hold ZVRA as of Q2 2025.

SignatureFD reported no remaining Zevra Therapeutics position as of Q2 2025 after selling out during the quarter.
SignatureFD sold 299 Zevra Therapeutics shares in Q2 2025, an estimated $2.24K.
SignatureFD first reported a position in Zevra Therapeutics in Q1 2021 and held it in 4 quarters.
SignatureFD's Zevra Therapeutics position peaked at $2.24K in Q1 2025.
120 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2025.

Based on SignatureFD's 13F filing for Q2 2025, filed 16 Jul 2025.